Kling Biotherapeutics

Kling Biotherapeutics is a clinical-stage biotechnology company located in Amsterdam, the Netherlands, focusing on developing novel antibody-based treatments for cancer and infectious diseases through its proprietary discovery platform. It has developed a robust pipeline based on the evaluation of B cells present in individuals with significant responses to cancer and infectious diseases. Its proprietary B cell immortalization platform enables rapid functional screening of antibodies and has led to the identification of antibodies targeting novel epitopes (cancer and infectious diseases) and cancer-associated antigens with unique post-translational modifications.